📋 Caribou Biosciences, Inc. (CRBU) - Clinical Trial Update
Filing Date: 2022-05-12
Accepted: 2022-05-12 10:03:28
Event Type: Clinical Trial Update
Event Details:
Caribou Biosciences Inc (CRBU) Announces Clinical Trial Update
Caribou Biosciences Inc (CRBU) provided an update on its clinical development programs.
Clinical Development Highlights:
Drug Program: held
Diseases/Conditions: Vienna
Clinical Stage: Phase 1 trial, Phase 1
Collaboration: the European Hematology Association
expected by year end. Details of the poster presentation at EHA are as follows: Title: First-in-human trial of CB-010, a CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knock out, in patients with relapsed or refractory B cell non-Hodgkin lymphoma (ANTLER study) Abstract: P1455
expected by YE 2022
planned for today at 10:15 am ET – -- Initial data scheduled to be shared at the European Hematology Association (EHA) 2022
📋 Caribou Biosciences, Inc. (CRBU) - Clinical Trial Update
Filing Date: 2022-05-12
Accepted: 2022-05-12 10:03:28
Event Type: Clinical Trial Update
Event Details:
💼 Business Developments:
No business developments data available.
Structured Data: